Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer

被引:0
|
作者
Dogan, Izzet [1 ]
Gurbuz, Mustafa [2 ]
Aydin, Esra [1 ]
Karabulut, Senem [1 ]
Tastekin, Didem [1 ]
Utkan, Gungor [2 ]
机构
[1] Istanbul Univ Inst Oncol, Med Oncol, Istanbul, Turkiye
[2] Ankara Univ, Med Oncol, Fac Med, Ankara, Turkiye
关键词
ABH blood group; gastric cancer; HER2/neu receptor; risk factors; RISK;
D O I
10.4103/jcrt.jcrt_1520_22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of study was to look at ABO/Rh blood types frequency and prognostic significance in patients with HER2/neu positive gastric cancer. Methods: The study was designed retrospectively. Clinicopathological characteristics, treatment approaches, and the ABO/Rh blood groups features were noted. The ABO/Rh blood types for patients and healthy donors were compared by the Chi-square method. Results: The average age was 61 years. The average survival time was 17.9 months (13.2-22.5). ABO blood types frequencies were not similar between patients (25.9% O, 6.3% AB, 57.1% A, and 10.7% B) and control group (34.9% O, 7.9% AB, 41.9% A, and 15.3% B) (P = 0.01). Patients and controls had the same Rh factor distribution (P = 0.07). Conclusions: We showed that A blood group frequency was increased in patients with HER2/neu receptor-positive gastric cancer than in a healthy population. Also, we detected that the frequency of O blood type was decreased. ABO/Rh blood types were not linked with prognosis for overall survival.
引用
收藏
页码:S747 / S751
页数:5
相关论文
共 50 条
  • [41] Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
    Shi, Hong-Zhi
    Wang, Yu-Ning
    Huang, Xiao-Hui
    Zhang, Ke-Cheng
    Xi, Hong-Qing
    Cui, Jian-Xin
    Liu, Guo-Xiao
    Liang, Wen-Tao
    Wei, Bo
    Chen, Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (10) : 1836 - 1842
  • [42] Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
    Hong-Zhi Shi
    Yu-Ning Wang
    Xiao-Hui Huang
    Ke-Cheng Zhang
    Hong-Qing Xi
    Jian-Xin Cui
    Guo-Xiao Liu
    Wen-Tao Liang
    Bo Wei
    Lin Chen
    World Journal of Gastroenterology, 2017, (10) : 1836 - 1842
  • [43] HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
    Anna Grenda
    Kamila Wojas-Krawczyk
    Tomasz Skoczylas
    Paweł Krawczyk
    Jadwiga Sierocińska-Sawa
    Grzegorz Wallner
    Janusz Milanowski
    BMC Gastroenterology, 20
  • [44] MOLECULAR-BIOLOGY AND IMMUNOHISTOCHEMISTRY OF GASTRIC-CANCER - ANALYSIS OF HER2/NEU ONCOGENE
    JAHNE, J
    URMACHER, C
    ALBINO, A
    MEYER, HJ
    PICHLMAYR, R
    CHIRURG, 1994, 65 (04): : 307 - 311
  • [45] Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Bang, Kyunghye
    Cheon, Jaekyung
    Park, Young Soo
    Kim, Hyung-Don
    Ryu, Min-Hee
    Park, Yangsoon
    Moon, Meesun
    Lee, Hyungeun
    Kang, Yoon-Koo
    GASTRIC CANCER, 2022, 25 (04) : 794 - 803
  • [46] Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Nomura, Shogo
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Asano, Hiromichi
    Ochiai, Atsushi
    Komatsu, Yoshito
    Sakamoto, Naoya
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 43 - 48
  • [47] Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma: More Is Better
    Huber, Aaron R.
    Buscaglia, Brandon
    Koltz, Brooke R.
    Henry, Jill
    McMahon, Loralee
    Guo, James
    Hicks, David G.
    Whitney-Miller, Christa L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 151 (05) : 461 - 468
  • [48] Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Cristina Grávalos
    Carlos Gómez-Martín
    Fernando Rivera
    Inmaculada Alés
    Bernardo Queralt
    Antonia Márquez
    Ulpiano Jiménez
    Vicente Alonso
    Rocío García-Carbonero
    Javier Sastre
    Ramon Colomer
    Hernán Cortés-Funes
    Antonio Jimeno
    Clinical and Translational Oncology, 2011, 13
  • [49] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    Gravalos, C.
    Jimeno, A.
    ANNALS OF ONCOLOGY, 2008, 19 (09) : 1523 - 1529
  • [50] HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
    Huang, Jun-Xing
    Zhao, Kun
    Lin, Mei
    Wang, Qi
    Xiao, Wei
    Lin, Mao-Song
    Yu, Hong
    Chen, Ping
    Qian, Rong-Yu
    ONCOLOGY LETTERS, 2013, 6 (01) : 13 - 18